Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Gut|June 4, 2024
DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancerAnna Brichkina, Miriam Ems, Roman Suezov, et al.
Cell Death and Differentiation|June 23, 2025
Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymesJan Dreute, Julia Stengel, Jonas Becher, et al.
Nature Communications|May 21, 2025
A searchable atlas of pathogen-sensitive lncRNA networks in human macrophagesNils Schmerer, Harshavardhan Janga, Michelle Aillaud, et al.
The EMBO Journal|November 9, 2019
Distinct IL-1α-responsive enhancers promote acute and coordinated changes in chromatin topology in a hierarchical mannerSinah-Sophia Weiterer, Johanna Meier-Soelch, Theodore Georgomanolis, et al.
Nature Genetics|January 8, 2025
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutationsJulianne S Funk, Maria Klimovich, Daniel Drangenstein, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 23, 2022
Single-cell RNA sequencing uncovers the nuclear decoy lincRNA PIRAT as a regulator of systemic monocyte immunity during COVID-19Marina Aznaourova, Nils Schmerer, Harshavardhan Janga, et al.
Cellular & Molecular Immunology|June 28, 2024
BAG6 restricts pancreatic cancer progression by suppressing the release of IL33-presenting extracellular vesicles and the activation of mast cellsBilal Alashkar Alhamwe, Viviane Ponath, Fahd Alhamdan, et al.
Journal of Virology|September 16, 2024
Distinct negative-sense RNA viruses induce a common set of transcripts encoding proteins forming an extensive networkNina Hofmann, Marek Bartkuhn, Stephan Becker, et al.
Cell Death and Differentiation|April 23, 2022
IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivityDennis Das Gupta, Christoph Paul, Nadine Samel, et al.
Leukemia|January 12, 2026
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)Andreas Burchert, Franck E Nicolini, Philipp le Coutre, et al.
Pageof 9